A Combined Treatment Effect of Cilostazol and Pentoxifylline in the Treatment of Peripheral Vascular Disease

Abstract

Background: In past comparative studies in peripheral vascular disease (PVD) showed Cilostazol was efficient in relieving intermittent claudication as compared to Pentoxifylline. Objectives: The present study was planned to assess the effect the combination of cilostazol (50 mg BD) and pentoxifylline (400 mg TDS) therapy in patients with PVD. Additionally, the adverse effects and economic burden of the combination was taken in to account. Methodology: An Observational antegrade study was done among 100 patients. A Patient with PVD visited to OPD of the vascular department was enrolled in the study. Data was collected as per the Case Record Form. Results: The mean age was found to be 58.4 ± 11.3 years of total 100 patients. An improvement in a Doppler testing (follow-up at the time interval after 1 month, 3 months and 6 months) and increased in peak systolic velocity in distal vessels as well as collaterals were observed in all patients. The PVD was prevalent in 50 to 60 years of age groups and hypertension and smoking were the most common risk factors present in PVD patients. There was more than 70% increase in walking distance after 24 weeks of treatment. Headache 24 (36.4%) and Dizziness 9 (13.6%) were observed as common side effect of therapy. The total cost of the combination therapy was affordable with improved quality of life. Conclusion: The combination treatment showed symptomatic improvement in peripheral vascular disease in the study. The peak systolic velocity gradually increased in the distal vessel and the combination was found to be cost-effective.